CPMD · Cannapharmarx, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Based on current financial projections, the Company does not have sufficient existing cash resources to fund its current operations. Accordingly, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 18, 2026
One customer — 63% of revenue (the year ended December 31, 2025)
“During the year ended December 31, 2025, the Company also recognized revenue of $861,476 (2024 - $nil) from the sale of cannabis products to a pharmaceutical company based in Germany. This comprised 63% of the revenues generated during the year ended December 31, 2025.”
One customer — 29% of revenue (the year ended December 31, 2025)
“During the year ended December 31, 2025, the Company recognized revenue of $394,633 (2024 - $770,265) from Cantek (Note 12), which was 29% of the total revenue (2024 - 94%).”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.7M | $1.36M | $820.14K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | |
| $3.21M | $3.45M | $3.76M | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$1.51M | -$2.08M | -$2.93M | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -153.06% | -357.86% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $324.15K | — | — | — | — | — | |
| $493.6K | $489.64K | $145.71K | $703.6K | $2.23M | $852.65K | $2.15M | $477.89K | $8763 | $6633 | $276.77K | $4.22M | $425.52K | $80.31K | $89.57K | $97.1K | $91.39K | $93.56K | |
| — | — | $116.64K | $703.6K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $0 | $126.96K | $128.26K | $0 | — | — | — | — | — | — | — | — | — | |
| — | — | $0 | $127.85K | $294.93K | $2708 | $128.51K | $129.04K | $0 | — | — | — | $0 | — | — | — | — | — | |
| $1.38M | $1.26M | $696.02K | $1.58M | $5.21M | $2.99M | $14.49M | $15.98M | $954.32K | $6633 | $1M | $11.65M | $3.97M | $80.31K | $89.57K | $97.1K | -$585.6K | -$113.74K | |
| -$2.89M | -$3.35M | -$3.63M | -$1.58M | -$5.21M | -$2.99M | -$14.49M | -$15.98M | -$954.32K | -$6633 | -$1M | -$11.65M | -$3.97M | -$80.31K | -$89.57K | -$97.1K | $585.6K | $113.74K | |
| — | -245.77% | -442.72% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | -$3.63M | -$1.45M | -$4.92M | -$2.99M | -$14.36M | -$15.85M | -$954.32K | — | — | — | -$3.97M | — | — | — | — | — | |
| $1.51M | $1.96M | $2.26M | $1.69M | $2.29M | $1.51M | $2.29M | $4.47M | $2.14M | $0 | $423 | $2724 | $5048 | — | — | — | — | — | |
| -$8.43M | -$7.78M | -$6.3M | $5.27M | -$3.32M | -$5.84M | -$5.4M | -$4.47M | -$2.14M | $0 | $3641 | -$90.47K | -$3947 | -$14.1K | -$8499 | -$2559 | -$10.2K | -$4875 | |
| — | — | $0 | -$78.76K | $0 | -$6.67M | $0 | -$7.07M | $0 | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | -$8.53M | -$8.83M | -$19.89M | -$20.45M | -$3.09M | -$6633 | -$1M | -$11.74M | -$3.98M | -$94.41K | -$98.07K | -$99.66K | $575.4K | $108.86K | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | |
| -$11.32M | -$11.13M | -$9.91M | $3.69M | -$8.53M | -$8.83M | -$19.89M | -$20.45M | -$3.09M | -$6633 | -$1M | -$11.74M | -$3.98M | -$94.41K | -$98.07K | -$99.66K | -$99.66K | $108.86K | |
| — | -817.19% | -1207.82% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$10.69M | -$11.74M | -$9.31M | $3.41M | -$7.92M | -$8.86M | -$20.37M | -$20.31M | -$3.09M | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | — | — | — | $0.04 | $0.12 | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.02 | -$0.02 | -$0.02 | $0.01 | $0.04 | $0.12 | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | — | — | 211.04M | 74.69M | 40.7M | — | — | — | — | — | 11.07M | 2.38M | 2.38M | 2.38M | — | — |
| shares | — | 662.5M | 625.28M | 308.94M | 211.04M | 74.69M | 40.7M | 31.17M | 17.96M | 17.96M | 17.96M | 15.34M | 11.07M | 2.38M | 2.38M | 2.38M | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2020: $98.96K in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Convertible notes payable, including current maturities | 2026-06-30 | USD 1,017,004 | 10-Q filed 2026-08-18 |
| Current operating lease liabilities | 2026-06-30 | USD 964,994 | 10-Q filed 2026-08-18 |
| Current portion of notes payable | 2026-06-30 | USD 423,345 | 10-Q filed 2026-08-18 |
| Loans payable, including current maturities | 2026-06-30 | USD 13,410,379 | 10-Q filed 2026-08-18 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Noncurrent operating lease liabilities | 2026-06-30 | USD 4,817,775 | 10-Q filed 2026-08-18 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 21 similar-size Drug Manufacturers - Specialty & Generic companies (of 101 listed).